- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00338585
Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery
January 8, 2008 updated by: ARCA Biopharma, Inc.
Phase 3, Multicenter, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Acute Peripheral Arterial Occlusion (NAPA-3)
The purpose of this study is to directly compare the safety and efficacy of intra-thrombus alfimeprase 0.3 mg/kg with placebo in acute peripheral arterial occlusion (PAO) as measured by a 30 day open vascular free surgery rate.
Study Overview
Detailed Description
There is an unmet medical need to improve thrombolytic therapy in acute peripheral arterial occlusion (PAO).
Currently used plasminogen activators can result in increased circulating levels of plasmin that result in a systemic "lytic state" that does not distinguish between physiologic and pathologic thrombosis.
In general, mean plasminogen activator infusion durations of greater than 24 hours in order to achieve successful thrombolysis are problematic in a disease where delayed restoration of arterial flow can lead to irreversible ischemic damage.
A direct thrombolytic agent like alfimeprase, with a rapid mechanism of action and a potentially safer bleeding risk profile, could facilitate a rapid restoration of arterial flow and avoidance of open vascular surgery.
Study Type
Interventional
Enrollment
300
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18 or older
- Arteriographically confirmed acute PAO of the lower extremity with onset of symptoms within 14 days prior to randomization
- Acute index limb ischemia classified as SVS/ISCVS Class I or IIa caused by occlusion of a native artery and/or bypass graft (vein or prosthetic). Only Class I subjects with abrupt onset of ischemic rest pain or abrupt onset/progression of lifestyle-limiting claudication are eligible
- Acute PAO with a need for urgent surgical intervention to restore arterial blood flow in the event of unsuccessful thrombolytic therapy
- Available for follow-up assessments
Exclusion Criteria:
- Contraindication to systemic anticoagulation
- History of endovascular procedure or open vascular surgery on the index limb within the past 30 days
- History of significant acute or chronic kidney disease that would preclude contrast angiography
- Known allergy to contrast agents
- History of heparin induced thrombocytopenia
- Participation in any study of an investigational device, medication, biologic, or other agent within 30 days prior to randomization
- Any thrombolytic therapy within 5 days prior to randomization
- Past participation in any alfimeprase trial
- Pregnant, lactating, or actively menstruating women or women of childbearing potential who are not using adequate contraceptive precautions
- Investigator inability to advance guidewire through index occlusion
- Any other subject feature that in the opinion of the investigator should preclude study participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Secondary Outcome Measures
Outcome Measure |
---|
AEs and SAEs
|
rate of arterial flow restoration
|
rate of improvement in index limb ABI
|
change in WIQ functional status scores
|
major bleeding events
|
ICH
|
peripheral arterial embolic events
|
all cause mortality
|
surgical and endovascular procedures
|
amputation
|
changes in chemistry, hematology, and coagulation parameters based on central laboratory measurements
|
anti-alfimeprase antibody
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Mohammad Hirmand, MD, ARCA Biopharma, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2006
Primary Completion (ACTUAL)
March 1, 2007
Study Completion (ACTUAL)
March 1, 2007
Study Registration Dates
First Submitted
June 15, 2006
First Submitted That Met QC Criteria
June 15, 2006
First Posted (ESTIMATE)
June 20, 2006
Study Record Updates
Last Update Posted (ESTIMATE)
January 15, 2008
Last Update Submitted That Met QC Criteria
January 8, 2008
Last Verified
January 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HA007
- NAPA-3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arterial Occlusive Diseases
-
Meshalkin Research Institute of Pathology of CirculationCompletedARTERIAL OCCLUSIVE DISEASERussian Federation
-
Medical Scientific Fund of the Mayor of ViennaCompletedPeripheral Arterial Occlusive DiseaseAustria
-
SanofiCompletedPeripheral Arterial Occlusive DiseaseUnited States, Finland
-
SanofiCompletedPeripheral Arterial Occlusive DiseaseUnited States, Switzerland
-
Ryazan State Medical UniversityRecruitingPeripheral Arterial Occlusive DiseaseRussian Federation
-
B. Braun Melsungen AGActive, not recruitingPeripheral Arterial Occlusive DiseaseGermany
-
Maquet CardiovascularCompletedPeripheral Arterial Occlusive DiseaseUnited States, Germany, Czechia
-
University Hospital Inselspital, BerneWithdrawnPeripheral Arterial Occlusive DiseaseSwitzerland
-
Flanders Medical Research ProgramAngioScore, Inc.CompletedPeripheral Arterial Occlusive DiseaseBelgium, Germany
-
Hull University Teaching Hospitals NHS TrustWithdrawnPeripheral Arterial Occlusive DiseaseUnited Kingdom
Clinical Trials on alfimeprase
-
ARCA Biopharma, Inc.CompletedThrombosis | Venous Thrombosis | Catheter OcclusionUnited States
-
ARCA Biopharma, Inc.CompletedThrombosis | Venous ThrombosisUnited States
-
ARCA Biopharma, Inc.CompletedCatheters, IndwellingUnited States
-
ARCA Biopharma, Inc.Health DecisionsCompletedArterial Occlusive Diseases | Thrombosis | Peripheral Vascular DiseasesUnited States
-
ARCA Biopharma, Inc.TerminatedAcute Ischemic StrokeUnited States, Canada
-
ARCA Biopharma, Inc.CompletedArterial Occlusive DiseasesUnited States